BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37844687)

  • 21. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.
    Chhabra S; Visotcky A; Pasquini MC; Zhu F; Tang X; Zhang MJ; Thompson R; Abedin S; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Douglas Rizzo J; Runaas L; Saber W; Shah NN; Shaw BE; Horowitz MM; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1876-1885. PubMed ID: 32653622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
    Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
    Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
    Weng G; Fan Z; Xue H; Huang F; Xu N; Jin H; Yu S; Ye Z; Fan J; Xuan L; Liu Q
    Front Immunol; 2022; 13():1036403. PubMed ID: 36389692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group.
    Kimura SI; Kameda K; Harada K; Saburi M; Okinaka K; Shinohara A; Uchida N; Nishijima A; Ozawa Y; Tanaka M; Kuriyama T; Katayama Y; Sawa M; Ikegame K; Kawakita T; Kanda Y; Nakamae H; Ara T; Kimura T; Sato A; Fukuda T; Atsuta Y; Nakasone H
    Transplant Cell Ther; 2022 Apr; 28(4):209.e1-209.e9. PubMed ID: 34995815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
    Puckrin R; Kwan ACF; Blosser N; Leyshon C; Duggan P; Daly A; Zepeda V; Stewart D; Chaudhry A; Storek J; Jamani K
    Cytotherapy; 2023 Oct; 25(10):1101-1106. PubMed ID: 37306643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.
    Diep PP; Rueegg CS; Burman MM; Brinch L; Bø K; Fosså K; Landrø L; Loge JH; Lund MB; Massey RJ; Myrdal OH; Pathak M; Rimstad L; Tanem KE; Tjønnfjord GE; Aaløkken TM; Ruud E
    J Adolesc Young Adult Oncol; 2023 Feb; 12(1):66-75. PubMed ID: 35544321
    [No Abstract]   [Full Text] [Related]  

  • 28. Ocular Chronic Graft-versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.
    Jeppesen H; Gjærde LK; Lindegaard J; Julian HO; Heegaard S; Sengeløv H
    Transplant Cell Ther; 2022 Dec; 28(12):833.e1-833.e7. PubMed ID: 36002105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors.
    Sy A; Chanson D; Berano Teh J; Wong FL; Nakamura R; Dadwal S; Armenian SH
    Cancer Med; 2021 May; 10(9):2956-2966. PubMed ID: 33835722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
    Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
    Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation.
    Rentscher KE; Carroll JE; Juckett MB; Coe CL; Broman AT; Rathouz PJ; Hematti P; Costanzo ES
    J Natl Cancer Inst; 2021 Oct; 113(10):1405-1414. PubMed ID: 33693799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
    Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
    J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
    Yuan J; Pei R; Su W; Cao J; Lu Y
    Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
    Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
    Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
    Novitzky-Basso I; Schain F; Batyrbekova N; Webb T; Remberger M; Keating A; Mattsson J
    PLoS One; 2023; 18(3):e0282753. PubMed ID: 36893113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.
    Booth G; Yu Y; Harlan RP; Jacoby CE; Tomic KM; Slater SE; Allen BE; Berklich EM; Knight RJ; Dela Cruz J; Fu R; Gandhi A; Cook RJ; Meyers G; Maziarz RT; Newell LF
    Cytotherapy; 2023 Apr; 25(4):423-431. PubMed ID: 36690537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study.
    Soejima T; Shiohara M; Ishida Y; Inoue M; Hayakawa A; Sato A; Kamibeppu K; Atsuta Y; Yamashita T
    Int J Hematol; 2021 Apr; 113(4):566-575. PubMed ID: 33386599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
    Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A
    Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
    Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
    Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.